Unsupervised deconvolution of dynamic imaging reveals intratumor
  vascular heterogeneity by Chen, Li et al.
1 
Unsupervised deconvolution of dynamic imaging reveals 
intratumor vascular heterogeneity and repopulation dynamics 
 
Li Chen1,3, Peter L. Choyke2, Niya Wang3, Robert Clarke4, Zaver M. Bhujwalla5,  
Elizabeth M. C. Hillman6, Ge Wang7 and Yue Wang3,† 
 
 
1Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, 
MD 20892, USA; 2Molecular Imaging Program, National Cancer Institute, National Institutes 
of Health, Bethesda, MD 20892, USA; 3Department of Electrical and Computer Engineering, 
Virginia Polytechnic Institute and State University, Arlington, VA 22203, USA; 4Lombardi 
Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA; 
5Department of Radiology and Radiological Science, Johns Hopkins University School of 
Medicine, Baltimore, MD 21205, USA; 6Department of Biomedical Engineering, Columbia 
University, New York, NY 10027, USA; 7Department of Biomedical Engineering, Biomedical 
Imaging Center, Rensselaer Polytechnic Institute, Troy, NY 12180, USA 
 
 
 
2 
With the existence of biologically distinctive malignant cells originated within the same 
tumor, intratumor functional heterogeneity is present in many cancers and is often 
manifested by the intermingled vascular compartments with distinct pharmacokinetics. 
However, intratumor vascular heterogeneity cannot be resolved directly by most in vivo 
dynamic imaging. We developed multi-tissue compartment modeling (MTCM), a 
completely unsupervised method of deconvoluting dynamic imaging series from 
heterogeneous tumors that can improve vascular characterization in many biological 
contexts. Applying MTCM to dynamic contrast-enhanced magnetic resonance imaging 
of breast cancers revealed characteristic intratumor vascular heterogeneity and 
therapeutic responses that were otherwise undetectable. MTCM is readily applicable to 
other dynamic imaging modalities for studying intratumor functional and phenotypic 
heterogeneity, together with a variety of foreseeable applications in the clinic.  
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Intratumor genetic or epigenetic heterogeneity has been found in many cancers as evidenced 
by deep sequencing selectively applied to different parts of the same tumor 1,2. Consequently, 
cancer cells display remarkable phenotypic variability, including ability to induce 
angiogenesis, seed metastases, and survive therapy 3-5. Advanced solid tumors often contain 
vascular compartments with distinct pharmacokinetics, comprising hypoxic regions and 
spatially intermingled irregular vasculature that is leaky and inefficient 6-8. The complexity of 
heterogeneity has clinical implications. A more heterogeneous tumor is more likely to fail 
therapy due to increased drug-resistant variants 3,5, and characteristics of the dominant cell type 
will not necessarily predict the behaviors of interest rooted in specific cells 4.  
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) provides a 
noninvasive in vivo method to evaluate tumor vasculature architectures based on contrast 
accumulation and washout 7,9. While DCE-MRI can potentially depict the intratumor 
heterogeneity of vascular permeability 10, the quantitative application of DCE-MRI has been 
hindered by its inability to accurately resolve vascular compartments with distinct 
pharmacokinetics due to limited imaging resolution 7,11. This indistinction among the 
contributions of different compartments to the mixed tracer signals can confound compartment 
modeling and deep phenotyping for association studies 4,12,13. The goal of the present work was 
to discern vascular heterogeneity and its changes in tumors using DCE-MRI and novel 
mathematical models, for personalized cancer diagnosis and treatment. 
We developed a computational method (multi-tissue compartment modeling - MTCM) 
for deconvolving intratumor vascular heterogeneity and identifying pharmacokinetics changes 
in many biological contexts 5,14,15. MTCM works by applying a convex analysis of mixtures 
that enables geometrically-principled delineation of distinct vascular structures from DCE-
MRI data (Fig. 1a-c). A formal mathematical description of the method and its detailed 
implementation is available in Methods. 
 
Results 
Overview of MTCM. Tumors to be analyzed by MTCM contain unknown numbers of distinct 
vascular compartments. The pixel-wise tracer concentration in a particular vascular 
compartment is modeled as being proportional to the local volume transfer constant of the 
vascular compartment (Method). Because there are often significant numbers of partial-volume 
pixels, MTCM instead estimates pharmacokinetic parameters (flux rate constants) via the time-
courses of pure-volume pixels (pixels whose signal is highly enriched in a particular vascular 
compartment). Convex analysis of mixtures identifies those pure-volume pixels present at the 
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vertices of the clustered pixel time series scatter simplex, without any knowledge of 
compartment distribution (Method). When the number of underlying vascular compartments is 
detected using the minimum description length (MDL) criterion, MTCM provides a completely 
unsupervised approach to characterize intratumor heterogeneity (Methods and Appendix 
1.Supplementary Discussion). 
Modeling the pharmacokinetics of each vascular compartment using pure-volume pixel 
time-courses allowed us to estimate individual compartment flux rate constants (Fig. 1d-e). 
Non-negative least-square estimation yielded pixel-wise local volume transfer constants 
(Methods and Fig. 1f). Using synthetic and mouse DCE-MRI experiments, we showed that 
MTCM can be used to estimate pharmacokinetic parameters in several vascular compartments 
simultaneously and to quantitatively reconstruct tissue-specific local volume transfer constants 
(Supplementary Data 1-2, Fig. 3, Supplementary Fig. 2 and Supplementary Tables 1-2). 
Furthermore, MTCM enabled quantitation of differences in tissue-specific vascular 
permeability across time (for example, therapeutic responses in longitudinal studies; Methods). 
Thus, the change in values of flux rate constants in a given vascular compartment could be 
determined, despite an expected difference in that vascular compartment’s relative abundance.   
We also analyzed the same realistic synthetic dataset using a “traditional” way of 
principal component analysis - PCA. By a comparison of the tracer concentration extracted by 
PCA (Figure 3e) to that estimated by MTCM (Figure 3d), we can see that tracer concentration 
curves estimated by PCA are highly fluctuant and significant deviated from the ground truth. 
In fact, similar unsatisfactory results produced by PCA or classic factor analysis have been 
observed in the earlier studies by us and others (Cinotti, Bazin et al. 1991, Zhou, Huang et al. 
1997, Hillman and Moore 2007, Hillman, Amoozegar et al. 2011). We should clarify that 
MTCM consists of two major analytic parts: convex analysis of mixtures (CAM) and 
compartment modeling (CM), where the CAM is a critical step that automatically identifies the 
pure tissue pixels and their time activity curves, followed by the CM that estimates the 
pharmacokinetics parameters without being contaminated by the partial-volume effect. In 
contrast, since PCA does not enforce the nonnegative constraint for tracer concentration 
estimation, a subsequent compartment modeling cannot be performed to estimate 
pharmacokinetic parameters.      
Intratumor vascular heterogeneity in breast cancer revealed by MTCM. In keeping with 
our goal to use MTCM to better uncover vascular heterogeneity in human tumors, we applied 
MTCM to DCE-MRI sequence data obtained from a case of advanced breast cancer (Fig. 1a). 
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In this breast tumor 7, vascular heterogeneity is characterized by active angiogenesis in the 
peripheral “rim” and concurrent inner-core hypoxia. Upon preliminary analysis using MDL, 
we found that a two-tissue compartment model of the fast and slow tracer clearance rates was 
sufficient to account for the variable permeability at the majority of pixels (Methods). Thus, 
we used pure-volume pixels associated with these two vascular pools to estimate tissue-specific 
flux rate constants and to reconstruct local volume transfer constant maps (Methods). MTCM 
reveals two vascular compartments with distinct flux rate constants (Fig. 1e). Accordingly, we 
detected distinct spatial patterns of specific local volume transfer constant in the two vascular 
compartments (Fig. 1f) with a significant fraction of partial volume pixels. 
Intratumor vascular heterogeneity identified by MTCM is consistent with the 
knowledge obtained from ex vivo microscopic and molecular studies 7,13. Defective endothelial 
barrier function is one of the better documented abnormalities of tumor vessels, resulting in 
functional heterogeneity in vascular permeability to macromolecules 7,11. As a tumor rapidly 
outgrows its blood supply, it requires neovessel maturation, often leaving an inner core of the 
tumor with regions where blood flow and oxygen concentration are significantly lower than in 
normal tissues 6. MTCM reconstructed local volume transfer constant maps correlate well with 
the differential gene expression known to regulate angiogenesis 7,13.  
 
Changes in intratumor vascular heterogeneity in longitudinal studies. We also detected 
changes in pharmacokinetic patterns among longitudinal DCE-MRI data from breast cancer 
acquired before, during, and after treatment (Fig. 2a), quantified as different flux rate constants 
over time (Methods and Supplementary Table 3). For example, the two vascular compartment 
time-activity curves revealed by MTCM in the baseline data are highly distinct (Fig. 2b). We 
detected significantly higher permeability in a fast-flow pool and slightly lower permeability 
in a slow-flow pool when compared with the normal state. In contrast, the interim response 
(Fig. 2c) exhibits vascular compartment time-activity curves that are distinct but much closer 
to each other, whereas the closing response (Fig. 2d) shows a significant decrease in 
permeability of the fast-flow pool. We also detected different local volume transfer constant 
maps (Fig. 2b-d) and changes in the fractions of partial-volume pixels (Supplementary Table 
4).     
 
Comparative studies using standard compartment modeling. We compared tissue-specific 
pharmacokinetics detected with MTCM to the results of a standard compartment analysis of 
(total) vascular pool within the region of interest. Total time-activity curves were indistinct 
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across time (Supplementary Fig. 2) owing to therapeutic effects in some parts of the tumor 
but not in others and large fractions of partial-volume pixels. In this longitudinal study, we 
deconvolved total time-activity curves into two phased therapeutic effects using MTCM: a 
transient “normalization” of abnormal yet surviving tumor vasculature together with the 
significant and consistent drop in the relative volume transfer constants 6,16. In contrast, 
standard analysis may not return informative results when both the flux rate constant and 
volume transfer constant change heterogeneously in response to therapy. These examples 
illustrate the ability of MTCM to discover intratumor vascular heterogeneity and to detect 
changes in each vascular compartment over time. Finally, we tested the applicability of MTCM 
to dynamic fluorescence imaging data acquired on a mouse after bolus injection of indocyanine 
green dye by deconvolving biodistribution dynamics of the major organs 17 (Supplementary 
Fig. 3). The dissected tissue compartments constitute anatomical structures of the mouse that 
agree well with a digital anatomical mouse atlas. 
 
Discussion 
Several previous studies have discussed the problem of intratumor vascular 
heterogeneity in compartment modelling 7,11,16,18, a major outstanding issue for the 
characterization of complex phenotypes and therapeutic responses. Some methods have 
addressed the estimation of multi-compartment pharmacokinetics in the presence of varying 
partial-volume effects, relying on known regions of pure-volume pixels and number of 
compartments 10,13,16,17. The significant advantage of our strategy is its ability to detect and 
quantify intratumor vascular heterogeneity without any type of external information. The 
benefits of such a method include its wide applicability, sensitive detection of heterogeneity 
dynamics, and reliance on longitudinal data from one single subject (Appendix 1. 
Supplementary Discussion).        
We have identified differential and heterogeneous changes in tissue-specific vascular 
pharmacokinetics in tumors during treatment that were undetected using standard analysis, 
including tumor islands of persistent enhancement that have escaped the effects of therapy 18. 
These results are particularly intriguing when considered together with recent imaging studies 
describing foci of resistant and more aggressive clones within a tumor 5,13. While it is not yet 
possible to assign causality, these in vivo results allowed us to propose new hypotheses 
regarding the complex relationships between intratumor heterogeneity, clonal repopulation, 
cancer stem-cell, and therapeutic efficacy 1,3,5,10,19. 
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In metastatic disease, recent studies have revealed the emergence of treatment-resistant 
subclones that were present at a minor frequency in the primary tumour 20. Thus, modeling 
cancer diagnosis and treatment in the future should involve characterization of subpopulations 
within the primary tumour, monitoring of clonal dynamics during treatment and eradication of 
treatment-emergent clones 21. To prospectively assess intratumor heterogeneity, profiling of 
multiregional tumour samples would be required. However, it is impractical and potentially 
risky to take multiple ‘random’ biopsies in every patient, owing to both sampling bias and the 
inability to resolve intermingled heterogeneity 22. MTCM would not only make longitudinal in 
vivo surveillance possible but also enable imaging-informed selective biopsies.  
The future challenges of applying MTCM lie in the gap between research experiments 
and clinical practice. Unlike high-quality data in well-designed research studies, clinical data 
are usually with limited spatial and/or temporal resolution, accompanied by higher noise level 
(Supplementary Fig. 4). Lower spatial resolution results in less pure-volume pixels and thus 
reduces the accuracy of MTCM; while limited temporal resolution prevents accurate 
differentiation and estimation of pharmacokinetic parameters associated with distinctive 
vascular compartments.  
So far we have tested MTCM method on DCE-MRI data, dynamic contrast-enhanced 
optical imaging data, and dynamic PET imaging data, acquired from both human tissue/organ 
and whole-body mouse model (e.g., Supplementary Fig. 4). Theoretically, the MTCM method 
can produce confident estimation on any ‘dynamic contrast-enhanced’ imaging data with 
sufficient quality (e.g., spatial and temporal resolution) 23-25. However, we should emphasize 
that there are a few fundamental assumptions behind the MTCM methodology, as specified in 
the newly proved theorems (e.g., linear convex combination, existence of pure-tissue pixels). 
As in most medical imaging analysis, object motion constitutes a major source of error and can 
significantly confound the modeling results. Currently, MTCM is limited to ‘parallel’ 
compartment models, while the CAM part of the MTCM algorithm is applicable to resolving 
partial-volume contamination problem independent of the compartment models being used for 
subsequent parameter estimation. 
 
Methods 
Multi-tissue compartment modeling of DCE-MRI series. Let us consider J-tissue 
compartment model of DCE-MRI series (the Jth tissue compartment corresponds to tracer 
plasma input, indexed by p), whose tracer concentration kinetics are governed by a set of first-
order differential equations (Fig. 1c) 26,27 
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where ( )jC t is the tracer concentrations in the interstitial space weighted by the fractional 
interstitial volume in tissue-type j  at time t  for j=1,…, J, where J is the total number of vascular 
compartments; ( )pC t  is the tracer concentration in plasma (tracer input function); measured ( )C t  is 
the measured tracer concentration; transjK is the unidirectional volume transfer constant 
(/min)from plasma to tissue-type j; ep, jk is the flux rate constants (/min) in tissue-type j; and 
pK  is the plasma volume27.  
 Solving (1) leads to ep,( ) ( ) exp( ),  =1, ..., -1j p jC t C t k t j J= ⊗ − , where ⊗ denotes the 
mathematical convolution, and ( ) ( )J pC t C t= . The spatial-temporal patterns of tracer 
concentrations (pixel time-course) can be expressed as28 
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where measured ( , )lC i t is the tracer concentration at time lt  at pixel i , L  is the number of sampled 
time points, trans trans1 1( ),..., ( )JK i K i−  are the local volume transfer constants of the tissue-types 1 to 
(J-1), at pixel i, respectively; and ( )pK i  is the local plasma volume at pixel i .  
 
Parallelism between multi-tissue compartment modeling and the theory of convex sets. 
Apply a sum-based normalization to pixel time-course measured ( , )lC i t  and using vector-matrix 
notation, we can re-express (2) as  
trans
measured 1
( ) ( )J j jji K i==∑C C ,                                                 (3) 
where trans ( )jK i is accordingly normalized over j , measured ( )iC  and jC  are the vector notations 
(over time) of pixel time course measured ( , )lC i t  and compartment time course ( )j lC t , respectively. 
Since trans ( )jK i  is always non-negative, as a non-negative linear combination of { }J j= C , the 
9 
set of pixel time-course { }measured measured ( )i= C  forms a subset of the convex set readily defined 
by the set of { }jC  
{ }trans trans transmeasured 1 1( ) ,  ( ) 0,  ( ) 1,  1,...,J Jj j j jj jK i K i K i i N= == ≥ = =∑ ∑C .             (4) 
 MTCM exploits the strong parallelism between the multi-compartment model (3) and 
the theory of convex set. The fundamental principle is that latent compartments are pure 
vasculatures in a tumor whose pharmacokinetics { }jC  reside at the extremities of the scatter 
simplex occupied by the pixel time-courses, and accordingly, the interior of the simplex is 
occupied by the partial-volume pixels (linear non-negative mixtures of compartments) (Fig. 
1b). Estimates of compartment pharmacokinetics may then be derived from the vertices of the 
multifaceted simplex that most tightly encloses the pixel time-courses and has the same number 
of compartments as vertices (Fig. 1d) 29.MTCM algorithm is supported theoretically by a well-
grounded mathematical frameworkas summarised below (see formal proofs in Appendix 2. 
Supplementary Method). 
 
Theorem 1 (Convexity of pixel time-course).Suppose that the J compartment 
pharmacokinetics { }jC  are linearly independent, and transmeasured 1( ) ( )
J
j jj
i K i
=
=∑C C where 
local volume transfer constants{ }trans ( )jK i are non-negative and have at least one pixel whose 
signal is highly and exclusively enriched in a particular vascular compartment, then, measured  
uniquely specifies a convex set { } { }measured measured1 1( ),  0,  1N Ni i ii iiα α α= == ≥ =∑ ∑C  which is 
in fact identical to the convex set { } { }1 1,  0,  1J JJ j j j jj jβ β β= == ≥ =∑ ∑C  , whose vertices 
are the J compartment pharmacokinetics{ }jC . 
Theorem 2 (Optimum source dominance). Suppose that the local volume transfer constants
{ }trans trans trans trans1( ) ( ),..., ( ),..., ( )j j m j J jv K v K v K v =  K  are the vertices of the pixel time-course 
scatter simplex. Then the MTCM solution based on these vertices { }trans ( )jvK achieves the 
maximum source dominance in the sense of trans trans
1,2,...
( ) max ( )m j mi NK v K i== .  
From Theorems 1 and 2, there is a mathematical solution uniquely identifying the 
compartment model (3) based on the observed set of pixel time-course { }measured measured ( )i= C
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(identifiability and optimality): The vertices of convex set { }measured  are the J compartment 
pharmacokinetics{ }jC when there is at least one pixel whose signal is highly and exclusively 
enriched in a particular vascular compartment(Fig. 1b). This means that, in principle, under a 
noise-free scenario, we can directly estimate { }jC  by locating the vertices of { }measured   
(Fig. 1d). 
 
Data preprocessing (Fig. 1a). First, the tumor area is extracted by masking out the non-tumor 
tissues surrounding the tumor site 30. Second, the first few image frames, such as the four initial 
images of DCE-MRI sequences in our experiments, are removed because they correspond to 
the time prior to sufficient onsite tracer uptake. Third, pixels whose temporal average signal 
intensity is lower than 5% of the maximum value, or whose temporal dynamic variation is 
lower than 5% of the maximum value, are eliminated, because these non-informative pixels 
could have a negative impact on subsequent analyses. Fourth, the pixel time series is 
normalized over time using a sum-based normalization scheme, focusing the analysis on the 
“shape” of pharmacokinetics rather than on absolute tracer concentration.  
 It is true that accurate extraction of tumor region is critical to any image-based analysis 
that is focused on tumor characterization, where non-tumor tissue would constitute a 
confounding factor. Theoretically, MTCM method can handle well such situation since it is a 
completely unsupervised approach, relying on the MDL-based model selection. Specifically, 
since MTCM is specifically designed to work on multiple tissue compartment modeling, when 
a significant portion of the surrounding healthy tissue is included in the processed ‘tumor’ area, 
the healthy tissue will be considered as an additional/individual compartment in Eq. (1) and 
Fig. 1c. The MDL-based model selection procedure will statistically determine the number of 
underlying tissue compartments in the processed area, e.g., whether the contribution of 
surrounding healthy tissues is significant to be considered as an independent compartment. 
Though MTCM methodology can accept the processed area extracted by any image 
segmentation methods, the tumor region in our study can be outlined by a collaborative effort 
by computer scientists and clinicians (Wang, Adali et al. 1998, Xuan, Adali et al. 2000, Li, 
Wang et al. 2001). In the case of heavy noise and fuzzy boundary, a consensus approach may 
be adopted that surveys the results of multiple methods. 
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Clustering of pixel time-course (Fig. 1b). To reduce the impact of noise/outlier data points, 
improve the efficiency of subsequent convex analysis of mixtures, and permit an automated 
determination of the number of underlying vascular compartments using the minimum 
description length (MDL) criterion, we aggregated pixel time-courses into representative 
clusters using a combined affinity propagation and expectation-maximization clustering 31 
(Appendix 2. Supplementary Method).As an initialization-free and near-global-optimum 
clustering method, affinity propagation clustering (APC) simultaneously considers all data 
points as potential exemplars and recursively exchange real-valued messages between data 
points until a high-quality set of exemplars and corresponding clusters gradually emerges. Let 
the “similarity” ( ),s i m  indicate how well the mth data point is suited to be the exemplar for 
ith data point; the “responsibility” ( ),r i m  reflects the accumulated evidence for how well-
suited the mth data point is to serve as the exemplar for the ith data point; the “availability” 
( ),a i m  reflects the accumulated evidence for how appropriate the ith data point chooses mth 
data point as its exemplar. Then, supposing that there are N data points (e.g., pixels) in total, 
the responsibilities ( ),r i m are computed based on  
( ) ( ) ( ) ( ){ }
' {1, ..., } '
, , max , ' , '
m N m m
r i m s i m a i m s i m
∈ ∩ ≠
← − + ,                                 (5) 
where the availabilities ( ),a i m  are initialized to zero and the competitive update rule (5) is 
purely data-driven. Whereas the responsibility update (5) allows all candidate exemplars to 
compete for ownership of a data point, the availability update rule 
( ) ( ) ( ){ }
' {1, ..., }, ' , '
, min 0, , max 0, ',
i N i i i m
a i m r m m r i m
∈ ≠ ≠
  ← + 
  
∑                           (6) 
collects evidence from data points to support a good exemplar, where the “self-availability” is 
updated differently ( ) ( ){ }
'
, max 0, ',
i m
a m m r i m
∉
←∑ . Then, the availabilities and responsibilities 
are combined to identify exemplars ( ){ }* arg max , ( , )
m
m a i m r i m= + . The update rules are 
repeated iteratively and terminated when no change occurs for 10 iterations 31.  
 
Convex analysis of mixtures (Fig. 1d). To identify the vertices of convex set { }measured  , we 
performed convex analysis of mixtures (CAM) on the obtained M cluster centers { }mC .We 
assumed J vascular compartments and conducted an exhaustive combinatorial search (with 
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total MJC  combinations), based on a convex-hull-to-data fitting criterion, to identify the most 
probable J vertices (Appendix 2. Supplementary Method). We used the margin-of-error 
{ }
1
, 1,... 1 1,... 2
min ,  0,  1,M
J J
J J
m j j j jm J C j jα α
δ α α α
∈ = =
= − ≥ =∑ ∑C C                     (7) 
to quantify the distance between mC  and convex set { }MJJ C∈  , where we have { }, 1,... 0MJm J Cδ ∈ =  
if mC  is inside { }MJJ C∈  . We then selected the most probable J vertices when the 
corresponding sum of the margin between the convex hull and the remaining “exterior” cluster 
centers reaches its minimum: 
{ }
{ }
{ }, 1,...1
1,...
1*,... * = arg min M
JM
J
M
m J Cm
J C
J δ
∈=
∈
∑ .                                    (8) 
 
Model selection procedure. One important discovery step concerning MTCM is to detect the 
number J of the underlying tissue compartments. We used MDL, a widely-adopted and 
consistent information theoretic criterion, to guide model selection (Appendix 2. 
Supplementary Method). We performed CAM on several competing candidates, and selected 
the optimal model that assigns high probabilities to the observed data while at the same time 
whose parameters are not too complex to encode 32. Specifically, a model is selected with J 
tissue compartments by minimizing the total description code length defined by  
( ) ( )( )( ) ( )1MDL log | log log( ),2 2M
J JMJ J M L−= − Θ + +                    (9) 
where ( )⋅  denotes the joint likelihood function of the clustered compartment model, M  
denotes the set of M cluster centers, and ( )JΘ  denotes the set of freely adjustable parameters 
in the clustered compartment model (see Supplementary Method).    
 
Estimation of pharmacokinetics parameters in MTCM. Having determined the pure-
volume pixels associated with the vertices of { }J   and the value of J, we estimated the 
values of tissue-specific vascular compartment pharmacokinetics parameters, i.e., flux rate 
constants { }ep, jk  and volume transfer constants { }transjK , where the vertex of fastest tracer 
enhancement (reaching its peak most rapidly) is identified as pC (Appendix 2. 
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Supplementary Method).We constructed the Toeplitz matrix ( )ep, jkH  (sampled system 
impulse response) and solved the following optimization problem 
{ } ( )
trans
ep ,
trans trans
ep, measured, ep, 2,
trans
ep,
ˆ ˆ, arg min
                        subject to 0 and 0
f f
j j j j j p
K k
j j
k K K k
K k
= −
> >
C H C
,                         (10) 
for 1,..., -1j J= . Subsequently, we estimated local volume transfer constants by solving 
( ){ }
( ){ }
( ) ( )
( )
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trans trans
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trans
ˆˆ arg min ( )
                                 subject to 0,  
j
J
j j j jj
K i
j
K i i K i k
K i j
=
= −
≥ ∀
∑C C
,                      (11) 
which readily reveals the intratumor vascular heterogeneity. 
 
Synthetic DCE-MRI datasets. We first validated MTCM-generated estimates of tissue-
specific vascular pharmacokinetics parameters using a set of realistic synthetic DCE-MRI data 
with known parameter values. We set J=3, indexing two tissue compartments and one plasma 
input. We generated a large number of synthetic DCE-MRI time series by multiplying the 
customized local volume transfer constant maps ( ){ }transjK i  with known compartment 
pharmacokinetics ( ){ }ep,j jkC . Synthetic data were comprised of 50 replicated datasets 
generated for each of the 12 parameter settings (Supplementary Data 1). We performed 
MTCM on all the datasets and compared the estimates of tissue-specific kinetic parameters 
produced by MTCM with the ground truth, in terms of both biases (accuracy) and variance 
(reproducibility) of the estimates, measured over 50 replicated datasets. For comparison 
purposes, we also evaluated the three most relevant methods (Supplementary Table 1).  To 
determine whether the proposed MDL criterion detects the correct number of underlying tissue 
compartments, we calculated the MDL values for 2, 3, ..., 6J = and identified the most 
probable value of J when MDL achieves its minimum value(s) (Fig. 3).  
 
Characterization of differential vascular pharmacokinetics in advanced breast cancer 
case. In the second application, we analyzed the real DCE-MRI data of an advanced breast 
tumor using both MTCM and the classic method. The T1-weighted gadolinium-enhanced (Gd-
DTPA)DCE-MRI data set was acquired by three-dimensional scans performed every 30 
seconds for a total of 11 minutes after the injection, on a 1.5 Tesla magnet using  three-
dimensional spoiled gradient-echo sequences (TR < 7 msec, TE < 1.5 msec, flip angle = 30°, 
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matrix = 192 × 256, 0.5 averages). Typically, 12-15 slices are obtained and 15-18 time frames 
are acquired for each case. We visually examined the convexity of projected pixel time-course 
via the top two convexity-preserved projections where the margin between the “exterior” data 
points and the convex hull is minimized. We observed that two-tissue compartments (a three-
vertex convex set) were sufficient to describe the observed pixel time-course scatter simplex. 
While additional compartments can be used to account for outlier vertices, these compartments 
become difficult to interpret. We analyzed the dataset by setting 4,5,6J =  and observed noise-
like and biologically implausible pharmacokinetics patterns. The minimum value of MDL 
confirmed J=3. The number of clusters M takes values between 12 and 18, determined 
automatically by the APC algorithm. 
 
Characterizing longitudinal changes of differential vascular pharmacokinetics in treating 
angiogenic-active breast cancer case. Vascular pharmacokinetics parameter values estimated 
by MTCM reveal longitudinal changes that may serve as the evidence of differential and 
heterogeneous responses to therapy. We analyzed the data sets arising from a longitudinal study 
of tumor response to anti-angiogenic therapy using similar imaging protocols (Supplementary 
Data 3). Three sets of DCE-MRI data were acquired during standard treatment, each three 
months apart, serving as the potential endpoints in assessing the response to therapy. To detect 
various yet potentially hidden changes accounting for intratumor heterogeneity, we applied the 
same MTCM and MDL (as well as the classic method) to the three data sets separately.  
 
Open source multiplatform standalone MTCM Java-R software. Java GUI supported 
MTCM was implemented in both R and MATLAB, and runs on both Microsoft Windows and 
Linux platforms (http://mloss.org/software/view/437/). MTCM takes input the .mat data files 
that record the pixel time-course of DCE-MRI data in matrices. Each row corresponds to a time 
frame and each column corresponds to a pixel. Results of MTCM are provided to the users via 
a Java-based GUI (Supplementary Fig. 5). 
 
Appendix 1. Supplementary Discussion 
Dynamic intratumor heterogeneity: clonal repopulation & multi-compartment model. 
For the characterization of complex phenotypes and therapeutic responses 5,7,11, a major 
outstanding issue is how to accurately quantify intratumor vascular heterogeneity that may be 
severely confounded by the varying partial-volume effect 7,16. Specifically, to capture the 
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changes (that may reflect the underlying ‘clonal’ repopulation dynamics 34) in (1) local volume 
transfer maps, (2) compartment pharmacokinetics, and (3) number of distinctive 
compartments, a completely unsupervised learning method is required to solve the multi-
compartment model based on only observed DCE-MRI data.      
MTCM using DCE-MRI has the potential to reveal functional intratumor vascular 
heterogeneity, without any type of external information, thus is an unbiased and data-driven 
approach. This advantage has significant implications. The recent results of Kreso et al. 
strongly suggest that biological differences between tumor cells can be due to additional 
mechanisms, other than genetic heterogeneities 34. It has been reported, despite validated 
genetic homogeneity, the different cancer ‘clones’ observed in a tumor, displayed notable 
differences in behavior during the experiments 34. More interestingly, some of these unusual 
clones remained inactive initially but reemerged at later stage; therapeutic drugs preferentially 
eliminated persistent clones while increased the proportion of clones that were initially dormant 
34. A more likely explanation about this clonal repopulation is the involvement of one or more 
distinct semistable epigenetic states, on which MTCM can help to reveal quantitatively at 
phenotypic and functional level. To our best knowledge, MTCM is the first tool of its type to 
address the suggestion that “Improved mathematical models built on actual clinical and 
experimental observations, will likely allow us to construct these pictures in the not-so-distant 
future 34.” For example, the results of MTCM may provide mechanistic models of tumor 
progression and responses to refine and optimize biopsy sampling, in terms of timing, number, 
and location of biopsies. Furthermore, some of form of intratumor heterogeneity (ITH) index 
may be subsequently defined as a predictor of tumor history and behaviour 38. 
In complex tissues, functional heterogeneity is of great interest since it represents the 
integration of various upstream factors. Since cell-cell signalling plays a critical role in tumor 
development and evolution, cellular heterogeneity may constitutes only a partial picture, and 
dissection based on cell types may provide limited information since functional aspect is 
largely missing 39. MTCM (a completely unsupervised method empowered by MDL based 
model selection) and DCE-MRI provide a powerful and in vivo method to reveal and quantify 
functional heterogeneity. In contrast, many conventional analytic methods (relying on prior 
knowledge) may miss the low-frequency yet critical subclone(s).    
 
Detecting the number of tissue compartment (model selection). 
To discover and characterize intratumor vascular heterogeneity, the true number of the 
underlying tissue compartments is an unknown ‘structural’ model parameter and must be 
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estimated from the data 33,34. To assure that MTCM provides a completely unsupervised 
machine learning method, we exploit the information theoretical criterion called minimum 
description length (MDL) 32,35, to detect the most appropriate number of tissue compartments 
in our analysis. From the MDL principle, we derived the specific MDL for MTCM model as 
Eq. (9) (see Supplementary Method).  
 MDL calculates the total number of ‘bits’ that are required to encode/explain both the 
‘data’ and ‘model’. When the model is given (or estimated), only information about ‘mismatch’ 
between model and data needs to be explained (or encoded). The first term (negative joint 
likelihood) in the MDL determines exactly the ‘bits’ for explaining the ‘data’ conditioned on 
the given model. The second and third terms represents the ‘penalty’ on the model complexity, 
that is, the total number of bits for explaining the model. Each of these terms involves two 
multiplicative factors: the number of free-adjustable parameters and the original data points 
used to estimate the parameter (or the original data points the parameter is used to or can 
‘explain’). Specifically, when estimating the compartment TCs (the column vectors of mixing 
matrix) { }1,...,J J= C C  parameterized by 1J −  independent epk , we use some form of 
vector-average operation (i.e., 
measured measured
1
, ,1,... 2
min
j j
m mJ
J
m m mjα α
α
=
−∑C Cμ μ ; where nonnegative 
1
, ... ,
Jm m
α α , with sum equal to 1, are the coefficients for defining a convex hull), the scalar 
entry ( )j lC t  in jC is estimated involving only M  scalar entries ( )measured , lm tµC  for a given lt , 
contributing total ( ) ( )1 log 2J M−  bits. Similarly, when estimating the local volume transfer 
constants (the row vectors of sources) trans ( )mK  with total JM  entries, we use some of form 
of vector-average operation (i.e., solving linear equations), where the scalar entry trans ( )jK m  in 
trans ( )mK  is estimated involving only L  scalar entries ( )
measured
, lm tµC  for a given m , 
contributing total log( ) 2JM L  bits.  
 
Data quality control (QC). 
Quality control should be applied to reduce error in all image parameters. The impact of motion 
should be assessed and tumours for which parameter estimates are unreliable should be 
rejected. The level of bulk motion can be assessed for each tumor by first extracting an 
averaged time series plot for each tumor region of interest (ROI) on each slice in the imaging 
volume and then by visual assessment of the dynamic time series images. In- and through-
plane motion can be investigated and a categorical score can be assigned for each tumor based 
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on the evaluations of bulk motion. Tumors with a motion assessment score higher than a pre-
specified threshold should be excluded 38. 
 
Appendix 2. Supplementary Method 
Parallelism between multi-compartment modeling and the theory of convex sets. 
We now discuss the identifiability of the compartment model (2) and the required conditions 
via the following definitions and theorems. 
 
Definition 1. Given a set of compartment TCs { }1,...,J J= C C , we denote the convex set it 
specifies by  
{ } { }1 1| ,  0,  1J JJ j j j J j jj jα α α= == ∈ ≥ =∑ ∑C C   .                          (S1)  
 
Definition 2. A compartment TC vector jC  is a vertex point of the convex set { }J   if it can 
only be expressed as a trivial convex combination of 1,..., JC C .    
 
Lemma 1 (Convex envelope of pixel time series). Suppose that the J compartment 
pharmacokinetics { }jC  are linearly independent, and transmeasured 1( ) ( )
J
j jj
i K i
=
=∑C C where 
spatially-distributed local volume transfer constants { }trans ( )jK i  are non-negative and 
normalized. Then, the elements of measured  (the pixel time series) are confined within a convex 
set { }J   whose vertices are the J compartment TCs 1,..., JC C .    
 
Definition 3. Any pixel whose associated normalized spatially-distributed volume transfer 
constants are in the form of trans WGP( )( )j ji ≈K e  is called a well-grounded point (WGP) and 
corresponds to a pure-volume pixel, where { }je  is the standard basis of J-dimensional real 
space (the axes of the first quadrant). In other words, we define pure volume pixels (or well-
grounded pixels) as the pixels that are occupied by only a single compartment tissue type. 
 
Proof of Lemma 1. By the definition of convex set 43, the fact that, { } trans,  ( ) 0ji j K i∀ ≥ , 
trans
1
( ) 1J jj K i= =∑  and transmeasured 1( ) ( )
J
j jj
i K i
=
=∑C C  readily yield { }measured ( ) Ji ∈C    where  
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{ } { }1 1| ,  0,  1J JJ j j j J j jj jα α α= == ∈ ≥ =∑ ∑C C   .                               (S2) 
Since 1,..., JC C  are linearly independent, it follows that  
1
 iff 0 J j j jj jα α= = = ∀∑ C 0                                                    (S3)  
that also implies that ∀j  
' ' '
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=  iff [ ,..., ]  J Tj j j J jj jα α α= = ∀∑C C e                                        (S4) 
i.e., jC  can only be a trivial convex combination of 1,..., JC C . Hence, by Definition 2, 
1,..., JC C  are therefore the vertices of convex set { }J  .        
 
Proof of Theorem 1.  Since ∃ WGP( )ji , 
trans
WGP( )( )j ji =K e  ∀j, and 
trans
measured 1
( ) ( )J j jji K i==∑C C , 
we have 
measured WGP( )( )j ji =C C .                                                     (S5) 
Then, for any { } { }1 1| ,  0,  1J JJ j j j J j jj jα α α= =∈ = ∈ ≥ =∑ ∑z C C   , we have 
{ }
{ }
1
measured WGP( )1
WGP( )' '
measured1
WGP( )
  ( )
, ,
  ( ),  where 
0, ,
J
j jj
J
j jj
j jN
i ii
j
i
i i
i
i i
α
α
α
α α
=
=
=
=
=
 ∈= = 
∉
∑
∑
∑
z C
C
C
                        (S6) 
that implies { } { }' ' 'measured measured measured measured1 1( ) | ( ) ,  0,  1N Ni i ii ii iα α α= =∈ = ∈ ≥ =∑ ∑z C C   , i.e., 
{ } { }measuredJ ⊆    . On the other hand, for any 
{ } { }' ' 'measured measured measured measured1 1( ) | ( ) ,  0,  1N Ni i ii ii iα α α= =∈ = ∈ ≥ =∑ ∑z C C   , we have 
measured1
trans
1 1
trans
1 1
trans
1 1 1
( )
  ( )
  ( )
   = ,  where ( ) and 1,
N
ii
N J
i j ji j
J N
i j jj i
J N J
j j j i j jj i j
i
K i
K i
K i
α
α
α
β β α β
=
= =
= =
= = =
=
=
 =  
= =
∑
∑ ∑
∑ ∑
∑ ∑ ∑
z C
C
C
C
                     (S7) 
that implies { } { }1 1| ,  0,  1J JJ j j j J j jj jα α α= =∈ = ∈ ≥ =∑ ∑z C C   , i.e., { } { }measured J⊆    . 
Combining { } { }measuredJ ⊆     and { } { }measured J⊆     gives { } { }measured J=    , and 
together with Lemma 1 readily completes the proof of Theorem 1. 
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Proof of theorem 2. Consider the pixel ( )trans trans1( *) * ( )
J
j jj
i i vα
=
= ∑K K  of the convex hull 
defined by the vertices { }trans ( )jvK  whose thm entry is the largest among all pixels, i.e., 
trans trans
1,2,...
( *) max ( )m mi NK i K i== . Since ( )1 * 1
J
jj
iα
=
=∑ , we may therefore write  
                                    ( )( ) ( )trans trans trans1 1( *) * ( *) * ( *)J Jm j m j mj jK i i K i i K iα α= == =∑ ∑ .          (S8) 
Alternatively, the thm entry of trans ( *)iK  can be expressed as 
                                                       ( )trans trans1( *) * ( )
J
m j m jj
K i i K vα
=
= ∑ .                                 (S9) 
By the unique convex expression of trans ( *)mK i , we have 
                                                  ( ) ( )trans trans1 * ( *) ( ) 0
J
j m m jj
i K i K vα
=
− =∑ ,                           (S10) 
which, together with the fact ( ) trans trans* 0 and ( *) ( ) 0j m m ji K i K vα ≥ − ≥ , implies { }* ji v∈ .    
 
Clustering of Pixel Time Series 
The purpose of multivariate clustering of normalized pixel time series is three-fold: 1) data 
clustering has proven to be an effective tool for reducing the impact of noise/outlier data points 
on model learning 44-46; 2) aggregation of pixel time series into a few clusters improves the 
efficiency of subsequent convex analysis of mixtures 36,37; 3) the resultant clustered 
compartment model permits an automated determination of the number of underlying tissue 
compartments using the minimum description length (MDL) criterion  33,38,39.  
There has been considerable success in using SFNMs to model clustered data sets such 
as DCE-MRI data, taking a sum of the following general form 40-42: 
( ) ( ) ( )trans trans transtrans trans trans, , ,1 1( ) ( ) | , ( ) | ,J Mm m mm m mm m Jp i g i g iπ π= = += +∑ ∑K K KK K e Σ K μ Σ , (S11) 
where the first term corresponds to the clusters of pure volume pixels ( )1,...,m J= , the second 
term corresponds to the clusters of partial volume pixels ( )1,...,m J M= + , M  is the total 
number of pixel clusters,  mπ  is the mixing factor,  ( )g ⋅  is the Gaussian kernel, me  denotes 
the mth natural basis vector corresponding to the mean vector of the mth pure tissue 
compartment, and trans ,mKμ  and trans ,mKΣ  are the mean vector and covariance matrix of cluster m
, respectively. It is worth noting that SFNMs are a flexible and powerful statistical modeling 
tool and can adequately model clustered structure with essentially arbitrary complexity by 
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introducing a sufficient number of mixture components. Thus, strict adherence of the (in 
general, unknown) ground-truth data distribution to the form in (9) is not required in most real-
world applications 40,41.  By incorporating (7) into (9), the SFNM model for pixel time series 
becomes: 
( ) ( ) ( )measured measured measuredmeasured measured , measured , ,1 1( ) ( ) | , ( ) | ,
J M
m m m m m mm m J
p i g i g iπ π
= = +
= +∑ ∑C C CC C a Σ C μ Σ              
(S12) 
where transmeasured , ,
T
m m
=C KΣ AΣ A  and transmeasured , ,m m=C Kμ Aμ , with [ ]1,..., J=C C C . Accordingly, 
the first term of (S12) represents the corner clusters and the second term of (S12) represents 
the interior clusters (as shown in Fig. 1).  From Theorem 1 and SFNM model (S12), the 
clustered pixel time series set measured  is (approximately) confined within a convex set whose 
corner centers are the J compartment TCs 1,..., JC C .  
 It has been shown that significant computational savings can be achieved by using the 
EM algorithm to allow a mixture of the form (S12) to be fitted to the data 40,41. Determination 
of the parameters of the model (S12) can be viewed as a “missing data” problem in which the 
missing information corresponds to pixel labels ( ),iml i m= I  specifying which cluster 
generated each data point with ( ),i mI  denoting the indicator function. When no information 
about  iml  is available, the log-likelihood for the model (10) takes the form 
measured measuredmeasured measured , ,
1 1
log ( | ) log ( ) | ,
N M
m m m
i m
g iπ
= =
  =    
∑ ∑ C CΘ C μ Σ  ,           (S13) 
where ( )⋅   denotes the joint likelihood function of SFNM and 
measured measured, ,
{ , , , }m m m mπ= ∀C CΘ μ Σ . If, however, we were given a set of already clustered data 
with specified pixel labels, then the log likelihood (known as the “complete” data log-
likelihood) becomes 
{ }measured measuredmeasured measured , ,
1 1
log ( , | ) log ( ) | ,
N M
im m m m
i m
l g iπ
= =
 =  ∑∑ C CL Θ C μ Σ  ,         (S14) 
where { | 1,..., ; 1,..., }iml i N m M= = =L . Actually, we only have indirect, probabilistic, 
information in the form of the posterior responsibilities imz  for each model m having generated 
the pixel time series measured ( )iC . Taking the expectation of (S14), we then obtain the complete 
data log likelihood in the form  
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{ }measured measuredmeasured measured , ,
1 1
log ( , | ) log ( ) | ,
N M
im m m m
i m
z g iπ
= =
 =  ∑∑ C CZ Θ C μ Σ  ,       (S15) 
in which the ( )measuredPr 1 | ( )im imz l i= = C  are constants, and { | 1,..., ; 1,..., }imz i N m M= = =Z . 
 Maximization of (S15) can be performed using the two-stage form of the EM algorithm, 
where the pixel labels iml  are treated as missing data as aforementioned.  At each complete 
cycle of the algorithm we commence with an “old” set of parameter values Θ . We first use 
these parameters in the E-step to evaluate the posterior probabilities imz  using Bayes theorem 
43 
( ) { }measured measured
measured measured
measured , ,
measured
* measured , * , ** 1
( ) | ,
Pr 1| ( ) ,  1,...,
( ) | ,
m m m
im im M
m m mm
g i
z l i m M
g i
π
π
=
  = = = ∈
  ∑
C C
C C
C μ Σ
C
C μ Σ
.           
(S16) 
These posterior probabilities are then used in the M-step to obtain “new” values Θ  using the 
following re-estimation formulas 
1
1 N
m im
i
z
N
π
=
= ∑ ,                                                         (S17) 
measured
measured1
,
1
( )N imi
m N
imi
z i
z
=
=
= ∑
∑
C
C
μ ,                                              (S18) 
( )( )measured measured
measured
measured , measured ,1
,
1
( ) ( )
TN
im m mi
m N
imi
z i i
z
=
=
− −
=
∑
∑
C C
C
C μ C μ
Σ .              (S19) 
 
Convex Analysis of Mixtures  
At this point in our analysis procedure, each pixel time-course is represented by a group of 
cluster centers, where both the dimensionality and noise/outlier effect are significantly reduced. 
Given the obtained M cluster centers 
measured measured,1 ,
,..., MC Cμ μ , CAM is applied to separate pure-
volume clusters from partial-volume clusters by detecting the “corners” of the convex hull 
containing all clusters of pixel TCs (theoretically supported by Lemma 1 and Theorem 1). 
Assuming the number of compartments J  is known a priori, an exhaustive combinatorial 
search (with total MJC  combinations), based on a convex-hull-to-data fitting criterion, is 
performed to identify the most probable J  corners. This explicitly maps pure-volume pixels 
to the corners and partial-volume pixels to the interior clusters of the convex hull. 
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Let { }measured 1 measured, ,,..., Jm mC Cμ μ  be any size-J subset of { }measured measured,1 ,,..., MC Cμ μ . Then, the 
margin (i.e., distance) between 
measured ,mC
μ  and the convex hull { }measured 1 measured, ,,..., Jm mC Cμ μ  is 
computed by 
( ) measured measured1
1
, ,, ,..., 1,... 2
min ,
j jJ m mJ
J
m m mm m m jα α
δ α
=
= −∑C Cμ μ                                    (S20) 
where 
1
0,  1
j j
J
m mj
α α
=
≥ =∑ . It shall be noted that if measured ,mCμ  is inside 
{ }measured 1 measured, ,,..., Jm mC Cμ μ  then  ( )1, ,..., 0Jm m mδ = . Next, we define the convex-hull-to-data fitting 
error as the sum of the margin between the convex hull and the “exterior” cluster centers and 
detect the most probably J corners with cluster indices ( )* *1 ,... Jm m  when the criterion function 
reaches its minimum: 
( )
( )
( )1
1
* *
1 , ,...,1
,...,
,... = arg min
J
J
M
J m m mmm m
m m δ
=∑ .                                     (S21) 
The optimization problems of (22) and (23) can be solved by advanced convex optimization 
procedure described in 43 and an exhaustive combinatorial search (for realistic values of J and 
M, in practice), respectively.  
 
Model selection procedure.  
One important issue concerning MTCM method is the detection of the structural parameter J 
in the model (the number of underlying tissue compartments or types), often called model 
selection 32,44,45. This is indeed particularly critical in real-world applications where the true 
structure of the compartment models may be unknown a priori. We propose to use a widely-
adopted and consistent information theoretic criterion, namely the minimum description length 
(MDL) 32,39,44, to guide model selection. The major thrust of this approach is the formulation 
of a model fitting procedure in which an optimal model is selected from several competing 
candidates, such that the selected model best fits the observed data. MDL formulates the 
problem explicitly as an information coding problem in which the best model fit is measured 
such that it assigns high probabilities to the observed data while at the same time the model 
itself is not too complex to describe.  
However, when the number of pixels is large as in DCE-MRI application, direct use of 
MDL may underestimate the value of J, due to the lack of “structure” in classical compartment 
models (over-parameterization) 33,38,39. We therefore propose to naturally adopt and extend the 
clustered compartment models into the MDL formulation 52. The proposed clustered 
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compartment model allows all pixels belonging to the same cluster to share a common transmK , 
thus greatly reducing model complexity for a given value of J (the number of convex hull 
corners). Specifically, a model is selected with J tissue compartments by minimizing the total 
description length defined by 33,44 
( ) ( )( )( ) ( )measured, 1MDL log | log log( ),2 2M
J JMJ J M L−= − Θ + +           (S22) 
where ( )⋅  denotes the joint likelihood function of the clustered compartment model, 
measured,M  denotes the set of M cluster centers, and ( )JΘ  denotes the set of freely adjustable 
parameters in the clustered compartment model.    
Our aim herein is to use MDL criterion 33,44 and the MTCM estimates to select the best 
value of J automatically (the number of convex hull corners or tissue compartments). In the 
clustered J-tissue compartment model, we allow all pixels belonging to the same cluster to 
share a common local volume transfer constant, namely transmK  with length J, 1,...,m M= . 
Letting measured,mC  be the mth cluster center associated with 
trans
mK , from (4), we can express the 
clustered compartment model as follows:  
                               [ ] transmeasured, 1,...,m J m= +C C C K n ,                                      (S23) 
where n  is the modeling residual noise assumed to follow zero-mean white Gaussian 
distribution 2~ ( , )N σ ⋅n 0 I  with variance 2σ .  
We specify ( )JΘ  as follows. From equations (3)-(4), 1 1,..., J −C C  are parameterized by 
ep, , 1, 2,..., 1jk j J= − . Furthermore, pC  is parameterized by 1 2 3 2 3{ , , , , }λ λ λ α α  based on the 
well-known exponential model 38,46. Then, together with trans trans1 ,..., MK K  and σ , we have  
( ) trans trans1 2 3 2 3 ep,1 ep,2 ep, 1 1{ , , , , , , ,... , ,..., , }J MJ k k kλ λ λ α α σ−Θ = K K . 
Based on MTCM estimated 1,..., JC C  determined by ˆ pC  and { }ep,ˆ , 1,..., 1jk j J= − , and 
trans
mK  and σ  obtained by the maximum-likelihood estimation,    
( )( ) [ ]( )trans trans 2measured, measured, 1
trans
ˆ arg max log( ( | )) arg min || ,..., || ,
               s.t. 0
m m
m M m J m
m
J
m
= Θ = −
≥ ∀
K K
K C C C K
K
 
 
( )( ) [ ] trans 2measured, measured, 1
1
1ˆ arg max log( ( | )) || ,..., ||
M
M m J m
m
J
M Lσ
σ
=
= Θ = −
⋅ ∑ C C C K  ,  
we can express the joint likelihood function in the MDL given by (S22) as   
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     ( ) ( ) [ ]
trans 2
/ 22 measured, 1
measured, 2
1
|| ,..., ||
( | ) 2 exp
2
M L m J m
M
m
J πσ
σ
−
=
 −
Θ = − 
 
∏
C C C K
  .     (S24) 
 
Estimation of pharmacokinetics parameters in MTCM. 
Having determined the probabilistic pixel memberships associated with pure-volume 
compartments, ijz  for 1,...,j J= , 1,...,i N= , we can then estimate the tissue-specific 
compartmental parameters, namely transjK and ep, jk , 1,...,j J= , directly from DCE-MRI pixel 
time series measured ( )iC , in which various compartment modeling techniques can be readily 
applied.  
To specify which “exterior” cluster is associated with which compartment, we 
investigate the temporal enhancement patterns of the “exterior” cluster centers. As 
aforementioned, pC  is associated with the cluster of the fastest enhancement (reaching its peak 
most rapidly); jC  is associated with the cluster of jth tissue type. We then compute pC  and 
jC  via 
measured measured1 1
1 1
( ) ( )
,      ,  1,..., -1
N N
iJ iji i
p jN N
iJ iji i
z i z i
j J
z z
= =
= =
= = =∑ ∑
∑ ∑
C C
C C  .                 (S25) 
We then recall the relationship trans ep,( ) ( ) exp( )j j p jC t K C t k t= ⊗ − , and discretize the convolution 
(with discretization interval t∆  (/min)) to the following vector-matrix notation   
( )transmeasured, ep, ,       1,..., -1j j j pK k j J= =C H C                                      (S26) 
by constructing a Toeplitz matrix 
  ( )
ep , 1
ep , 2 ep , 1
ep , ep , 1 ep , 2 ep , 1
ep,
0 0 ... 0
0 ... 0
... ... ... ... ...
...
j
j j
j L j L j L j
k t
k t k t
j
k t k t k t k t
e
e ek t
e e e e− −
−
− −
− − − −
 
 
 = ∆ 
 
  
H                      (S27) 
that is the sampled system impulse response. Then, the estimate of ep, jk  and 
trans
jK  can be 
obtained by solving the following optimization problem 
{ } ( )
trans
ep,
trans trans
ep, measured, ep, 2,
trans
ep,
ˆ ˆ, arg min
                        . . 0, 0
f f
j j j j j p
K k
j j
k K K k
s t K k
= −
> >
C H C
                            (S28) 
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for 1,..., -1j J= . Finally, we can calculate the compartment TCs ( )ep,1 ep, 1ˆ ˆ, ,...,p Jk k −C C  based 
on pC and ep,1 ep, 1ˆ ˆ,..., Jk k − , and then estimate the local volume transfer constants 
trans trans trans
1 1( ) ( ),..., ( ), ( )
T
J pi K i K i K i− =  K  based on equation (4) via 
( )
( ) ( ) ( )
( ) ( ) ( )
trans
trans trans
measured ep,1 ep, 1
2
trans trans
1 1
ˆ ˆˆ ( ) arg min , ,...,
                        . . 0,..., 0, 0,
p J
i
J p
i i k k i
s t K i K i K i
−
−
= −
≥ ≥ ≥
K
K C C C K
                    (S29) 
that reflects the spatial heterogeneity of vascular permeability 53.   
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Figure Legends 
Figure 1 | The proposed multi-tissue compartment modeling pipeline for uncovering intratumor 
vascular heterogeneity. (a) On the DCE-MRI sequence, tumor region is extracted using a digital 
mask. Then, pixel time-courses are collected and normalized over time. (b) Pixel time-courses 
are grouped into clusters with initialization-free multivariate clustering techniques. On the 
simplex of pixel time-courses, the clusters present at the vertices are identified by a convex 
analysis of mixtures. (c) Using pure-volume pixels, multi-compartment modeling is performed 
to estimate tissue-specific flux rate constants and volume transfer constants. (d) Scatter simplex 
of real DCE-MRI data from an advanced breast cancer. (e) Estimated tissue-specific 
compartmental time-activity curves: ‘blue’ – plasma input function; ‘red’ – fast flow kinetics; 
‘green’ – slow flow kinetics; and example images of the associated local volume transfer 
constants. (f) Illustrative microscopic images of normal and abnormal vessel architecture 
(McDonald and Choyke, Nat Med 9, 2003). 
Figure 2 | Quantitative estimates of tissue-specific pharmacokinetic parameters in a 
longitudinal breast cancer study reveal changes in tumor vascular behavior in response to 
hybrid anti-angiogenesis chemotherapy. While tumor size regression (largely determined by 
bulk tumor populations rather than rarer cancer stem cells) is clearly observed, together with a 
transient “normalization”, the detected tumor islands of persistent enhancement predict the 
confirmed recurrence despite the dramatic size changes . (a) Snapshots of DCE-MRI sequences 
taken from the same tumor before, during, and after therapy. (b) Scatter simplex of baseline 
DCE-MRI data taken before therapy; estimated tissue-specific compartmental time-activity 
curves; and example images of the associated local volume transfer constants. (c) Scatter 
simplex of interim DCE-MRI data taken during therapy; estimated tissue-specific 
compartmental time-activity curves; and example images of the associated local volume 
transfer constants. (d) Scatter simplex of closing DCE-MRI data taken after therapy; estimated 
tissue-specific compartmental time-activity curves; and example images of the associated local 
volume transfer constants. 
 
Figure 3 | MTCM estimates time-activity curves in multiple vascular compartments 
simultaneously and quantitatively reconstructs tissue-specific local volume transfer constants 
- synthetic DCE-MRI experiments: (a) synthesis of image series; (b) scatter simplex of 
synthesized image series; (c) tissue-specific compartmental tracer concentration curves and 
local volume transfer constant maps, estimated by MTCM; (d) MDL model selection to detect 
the number of compartments; (e) tissue-specific compartmental tracer concentration curves 
estimated by principle component analysis (PCA).  
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Support Information 
Supplementary Figure 1 – MTCM estimates time-activity curves in multiple vascular 
compartments simultaneously and quantitatively reconstructs tissue-specific local volume 
transfer constants – mouse DCE-MRI experimental data. (a) Snapshots of DCE-MRI sequence 
taken from the same tumor at 26 time points. Time point 1 is pre-contrast, and time points 2-
26 are post-contrast. The first two time points are removed in the experiment. Each time point 
contains 4 sections from the same tumor. (b) The MDL curve of model selection and 3 is the 
optimal choice corresponding to the minimum MDL value. (c) Estimated tissue-specific 
compartmental time-activity curves: ‘blue’ - plasma input function; ‘red’ – fast flow kinetics; 
‘green’ – slow flow kinetics. (d) Estimated maps of local volume transfer constants from four 
sections in the same tumor. 
Supplementary Figure 2 – Comparison of time-activity curves of total vascular pool within the 
region of interests and tissue-specific time-activity curves estimated by MTCM, in a 
longitudinal DCE-MRI study on a breast cancer tumor: (a)-(c) time-activity curves of total 
vascular pool; (d)-(f) MTCM-estimated time-activity curves of fast flow pool; (g)-(i) MTCM-
estimated time-activity curves of slow flow pool; (j)-(l) MTCM-estimated time-activity curves 
of plasma input function. 
Supplementary Figure 3 – MTCM dissects tissue compartments into anatomical structures of 
the mouse using dynamic fluorescence molecular imaging data acquired on a mouse after bolus 
injection of indocyanine green dye, allowing the longitudinal identification of the internal 
organs. (a) Physiologically interpretable biodistribution dynamics of the major organs with ten 
fluorescence time courses showing distinct patterns of circulating, accumulating, or 
metabolizing the dye in different organs. (b) The merged and color-coded maps of the dissected 
tissue compartments agree well with a digital anatomical mouse atlas. (c) The gray-scale maps 
of the dissected individual tissue compartment (Kidney: Ktrans=1.0004, kep=0.0134; Spine: 
Ktrans=1.0269, kep=0.0241; Antipose: Ktrans=0.7333, kep=0.0100; Large intestine: Ktrans=0.7808, 
kep=0.0203; Nodes: Ktrans=0.6719, kep=0.0049; Blood vessels: Ktrans=0.9891, kep=0.0222; Liver: 
Ktrans=0.7839, kep=0.0128; Brain: Ktrans=0.7553, kep=0.0258; Stomach: Ktrans=0.8955, 
kep=0.0143; Lung: Ktrans=0.6656, kep=0.0167). 
Supplementary Figure 4 – MTCM estimates time-activity curves in multiple DCE-MRI data 
produced in clinical practice. (a)-(c) show raw image series, scatter simplex of image series 
and estimated tissue-specific compartmental time-activity curves and local volume transfer 
constant maps, respectively for a case; (d)-(f) display the same things for another case. 
Supplementary Figure 5 – MTCM software package in R and Java is developed to implement 
MTCM algorithm, as well as the other algorithms widely used in blind source separation. The 
user-friendly Java GUI (a) can generate the tissue-specific local volume transfer constants and 
pharmacokinetic parameters on the right. Two pop-up windows (b) will show the projection of 
clustered pixels on the simplex, and (c) will display the estimated tissue-specific 
compartmental time-activity curves. 
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Supplementary Table 1 – Comparison of tissue-specific kinetic parameter estimation by 
MTCM and three most relevant methods, based on synthetic DCE-MRI experimental data. 
Supplementary Table 2 – Tissue-specific kinetic parameter estimates by MTCM on mouse 
DCE-MRI experimental data. 
Supplementary Table 3 – MTCM estimates of flux rate constants and volume transfer constants 
of a breast cancer tumor before, during, and after treatment in the longitudinal study. 
Supplementary Table 4 – Fractions of partial-volume pixels before, during, and after treatment 
in the longitudinal study. 
Supplementary Table 5. MTCM estimated tissue heterogeneity score before, during, and after 
treatment in the longitudinal study. 
 
Supplementary Data 1 – Synthetic datasets generated for 12 parameter settings. 
Supplementary Data 2 –DCE-MRI data sets arising from mouse DCE-MRI experiments. 
Supplementary Data 3 –DCE-MRI data sets arising from a longitudinal study of tumor response 
to anti-angiogenic therapy. 
 
 
